Martin E Gore
Overview
Explore the profile of Martin E Gore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
4205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gudd C, Au L, Triantafyllou E, Shum B, Liu T, Nathwani R, et al.
J Hepatol
. 2021 Feb;
75(1):177-189.
PMID: 33631227
Background & Aims: Checkpoint inhibitor-related hepatitis (CPI-Hep) is an emerging clinical challenge. We aimed to gain insights into the immunopathology of CPI-Hep by comprehensively characterising myeloid and lymphoid subsets. Methods:...
2.
Mcdermott D, Huseni M, Atkins M, Motzer R, Rini B, Escudier B, et al.
Nat Med
. 2018 Oct;
24(12):1941.
PMID: 30291359
In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun....
3.
Mcdermott D, Huseni M, Atkins M, Motzer R, Rini B, Escudier B, et al.
Nat Med
. 2018 Jun;
24(6):749-757.
PMID: 29867230
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma....
4.
Tannir N, Figlin R, Gore M, Michaelson M, Motzer R, Porta C, et al.
Clin Genitourin Cancer
. 2017 Jul;
PMID: 28711490
Background: We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) > 18...
5.
Rafii S, Gourley C, Kumar R, Geuna E, Ang J, Rye T, et al.
Oncotarget
. 2017 Apr;
8(29):47154-47160.
PMID: 28454085
Background: The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in only...
6.
George A, Kristeleit R, Rafii S, Michie C, Bowen R, Michalarea V, et al.
Eur J Cancer
. 2017 Mar;
76:52-59.
PMID: 28273485
Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug...
7.
Gore M, Jones R, Ravaud A, Kuczyk M, Demkow T, Bearz A, et al.
BJU Int
. 2016 Dec;
119(6):846-853.
PMID: 27981711
Objective: To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell carcinoma (mRCC). Patients And Methods: Intra-patient dose escalation may enhance the clinical benefit of targeted...
8.
Schmid T, Gore M
Ther Adv Urol
. 2016 Dec;
8(6):348-371.
PMID: 27904651
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment...
9.
Bolton K, Tyrer J, Song H, Ramus S, Notaridou M, Jones C, et al.
Nat Genet
. 2015 Dec;
48(1):101.
PMID: 26711112
No abstract available.
10.
Porta C, Gore M, Rini B, Escudier B, Hariharan S, Charles L, et al.
Eur Urol
. 2015 Jul;
69(2):345-51.
PMID: 26215605
Background: Metastatic renal cell carcinoma (mRCC) patients receiving first-line sunitinib typically survive >2 yr, with chronic treatment sometimes extending to ≥6 yr. Objective: To analyze long-term safety with sunitinib in...